Skip to content
Search

Latest Stories

Bopanna-Sutjiadi Pair reaches US Open mixed doubles semis

The eighth-seeded Bopanna-Sutjiadi duo secured a 7-6(4), 2-6, 10-7 win against the fourth-seeded Ebden-Krejcikova pair in the quarterfinal match.

In the upcoming semifinal, Bopanna and Sutjiadi will face the American team of Donald Young and Taylor Townsend. (Photo credit: X/@India_AllSports)
In the upcoming semifinal, Bopanna and Sutjiadi will face the American team of Donald Young and Taylor Townsend. (Photo credit: X/@India_AllSports)

INDIAN tennis player Rohan Bopanna and his Indonesian partner Aldila Sutjiadi advanced to the semifinals of the US Open mixed doubles after a challenging victory over Australian Matthew Ebden and Czech player Barbora Krejcikova.

The eighth-seeded Bopanna-Sutjiadi duo secured a 7-6(4), 2-6, 10-7 win against the fourth-seeded Ebden-Krejcikova pair in a quarterfinal match that lasted one hour and 33 minutes on Monday night.


Earlier in the tournament, Bopanna and Sutjiadi had defeated the Australian duo of John Peers and Katerina Siniakova from the Czech Republic, winning 0-6, 7-6(5), 10-7 in the second round.

In the upcoming semifinal, Bopanna and Sutjiadi will face the American team of Donald Young and Taylor Townsend.

Bopanna, 44, had exited the men’s doubles competition after he and his partner Ebden, the second seeds, lost 1-6, 5-7 to the 16th-seeded Argentine pair of Maximo Gonzalez and Andres Molteni in the third round.

Bopanna and Ebden had previously won the Australian Open earlier this year.

Having already announced his retirement from the Davis Cup, it remains to be seen if the 44-year-old Bopanna will return to defend his Australian Open title in January 2025.

(With inputs from PTI)

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less